[Translation] A multicenter, randomized, double-blind, active-drug parallel-controlled Phase II/III clinical study to evaluate the efficacy, safety, and immunogenicity of subcutaneous injection of MW05 or Jinyouli® per cycle in preventing chemotherapy-induced neutropenia in breast cancer patients
以津优力®作为阳性对照,比较MW05在乳腺癌患者中预防化疗引起的中性粒细胞减少症的有效性、安全性和免疫原性。
[Translation] Using Jinyouli® as a positive control, the efficacy, safety and immunogenicity of MW05 in preventing chemotherapy-induced neutropenia in breast cancer patients were compared.